Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suven Life Sciences, a pure R&D-focused pharma company, reported its Q1 FY26 results with standalone revenue from operations rising about 86% year-on-year to Rs. 186.67 lakhs (from Rs. 100.60 lakhs). However, other income fell sharply to Rs. 58.90 lakhs from Rs. 393.10 lakhs, dragging total income lower at Rs. 245.57 lakhs. Standalone net loss widened to Rs. 1,477.87 lakhs from Rs. 766.59 lakhs a year ago, while consolidated net loss nearly doubled to Rs. 5,151.69 lakhs (from Rs. 2,803.97 lakhs) as subsidiary Suven Neurosciences Inc ramped up R&D spend to Rs. 4,148.84 lakhs. The company raised Rs. 291.66 crores via convertible warrants issued on a preferential basis to 23 allottees at Rs. 134 per share. Statutory auditor Karvy & Co issued an unqualified limited review report on both sets of results.
Persistent and widening losses highlight the company's heavy R&D burn with little near-term revenue visibility, though the Rs. 291 crore warrant proceeds strengthen the balance sheet to fund development. For shareholders, the stock remains a long-term bet on its drug pipeline rather than near-term earnings.